Loading stock data…
CVS Health Corporation (CVS)
$96.74-0.46 (-0.47%)
Pre-Market$96.15-0.59 (-0.61%)· Last close Sep 4
CVS Health Corporation provides health solutions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CVS Health Corporation in the Healthcare sector is trading at $96.74 with a market capitalization of $123.7B. Wall Street consensus targets $116.04 (25 analysts), implying a +20.0% move over the next 12 months. The stock is currently 13% below its 52-week high of $110.68, remaining 13.0% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $100.43B↓ | $105.69B↑ | $102.87B↑ | $98.92B |
| Gross Profit | — | $15.62B↑ | $13.57B↓ | $13.81B↑ | $13.59B |
| Operating Income | — | $4.68B↑ | $2.11B↓ | $2.52B↑ | $2.38B |
| Net Income | — | $2.94B | $2.94B↑ | -$3.98B↓ | $1.02B |
Peer Comparison
JNJUNHPFE
Fundamentals
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and beha...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$123.73B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.53
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.75%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.14%
Volume
Today's trading volume
4.48M
Recent News
The Shingles Vaccine Is $0 at the Pharmacy. Get the Same Shot at Your Doctor’s Office and the Front Desk Asks for $200 Per Dose.
The shingles vaccine costs nothing under Medicare Part D, yet thousands of beneficiaries walk out of their doctor's office owing hundreds of dollars for the exact same shot. The billing system has a gap, and most patients have no idea it exists until they're already holding the receipt.
Here's How CVS Is Focusing on Aetna's Profitability Turnaround
CVS Health is advancing Aetna's profitability turnaround, supported by stronger Health Care Benefits results, an improved MBR and operational initiatives.
CVS Health (CVS) Stock Looks Below Fair Value But Mixed After 65% Return
CVS Health stock has delivered a strong 64.8% return over the past three years, and the current valuation picture is not a clear bargain or a clear stretch. Recent gains sit alongside a mixed value score and fresh headlines around its health insurance and compliance record, which give investors a few moving parts to weigh. The 64.8% three year return highlights how much value the market has already credited to CVS Health, so fresh buyers now have to judge whether that past performance still...
CVS Health (CVS) Makes Updated 2026 2027 COVID 19 Vaccines Available Nationwide
CVS Health (NYSE:CVS) announced that updated 2026-2027 COVID-19 vaccines are now available at CVS Pharmacy and MinuteClinic locations across the United States. The company is offering the new vaccines nationwide, with appointments and walk-in options across its retail and clinic network. CVS Health is integrating COVID-19 shots with other vaccinations, aiming to streamline access to multiple immunizations in a single visit. This kind of broad vaccine rollout highlights how large pharmacy...
Jim Cramer Says “Own It, Don’t Trade It” as CVS Health Gains Momentum
A caller on the September 2 episode of Mad Money noted that CVS Health Corporation (NYSE:CVS) is up 21% this year, sports a 3% dividend, and trades at a 28 valuation compared to its 54 average. Pointing to raised guidance, higher price targets, and a massive capital plan, they asked if it makes sense to […]